LFG
TVRD

Larson Financial Group’s Tvardi Therapeutics TVRD Stock Holding History

Larson Financial Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4 Hold
2
– – ﹤0.01% 3753
2026
Q1 		$6 Hold
2
– – ﹤0.01% 3613
2025
Q4 		$9 Buy
+2
New +$18 ﹤0.01% 3427

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Larson Financial Group's TVRD Position: Q2 2026 in Review

Larson Financial Group held its Tvardi Therapeutics (TVRD) position steady in Q2 2026 at 2 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #3753.

Larson Financial Group first reported a position in TVRD in Q4 2025 and has held it in 3 quarters since. The position peaked at $9 in Q4 2025. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Larson Financial Group held 2 shares of Tvardi Therapeutics worth $4 as of Q2 2026.
  • Larson Financial Group left its Tvardi Therapeutics share count unchanged in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3753 holding.
  • Larson Financial Group first reported a position in Tvardi Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Larson Financial Group's Tvardi Therapeutics position peaked at $9 in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.